NEW YORK (GenomeWeb) – As part of its overall strategy for sustained growth, Thermo Fisher Scientific has been developing a number of new clinical research and diagnostic products, ranging from US Food and Drug Administration-cleared immunoassays to next-generation sequencing-based panels, and is partnering with others to develop molecular diagnostic kits.

In a conference call yesterday to discuss the company's third quarter earnings, CEO Marc Casper highlighted several of the firm's recent initiatives and product launches in the clinical arena.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.